ArticleJournal of asthma and allergy2026
Montelukast Prescription Prevalence and Impact on Clinical Outcomes Among Patients with Asthma: A Cross-Sectional Study in Saudi Arabia.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although montelukast is widely prescribed as an add-on therapy for asthma management, the current rate of montelukast prescription and its association with clinical outcomes among asthmatic patients in Saudi Arabia are unknown. In addition, the U.S. Food and Drug Administration has recently issued a warning regarding potential serious neuropsychiatric adverse effects associated with montelukast use. Therefore, this study aimed to evaluate the prevalence of montelukast prescription and its impact on clinical outcomes among asthmatic patients in Saudi Arabia. Methods: A cross-sectional study was conducted among asthmatic patients attending a pulmonary clinic. Clinical and demographic data were obtained from medical records, while anxiety, depression, inhaler adherence, asthma control, and quality of life were assessed using validated questionnaires. Group differences were analyzed using independent Results: A total of 213 patients with asthma were included in the study; 103 were using montelukast, and 110 were not. The prevalence of montelukast prescription was 48%. Anxiety symptoms were higher among montelukast users compared with non-users (44.6% vs 15.5%), as were depressive symptoms (33.0% vs 11.0%). Montelukast use was significantly associated with increased odds of anxiety symptoms (aOR 4.1, 95% CI 2.01-8.45; P < 0.0001) and depressive symptoms (aOR 4.3, 95% CI 1.92-9.86; P < 0.0001). However, adherence to inhalers, asthma control, and quality of life were not significantly associated with montelukast use. Conclusion: Montelukast prescription was common among asthmatic patients in Saudi Arabia and was associated with higher levels of anxiety and depressive symptoms. Clinicians should consider monitoring psychological symptoms in patients receiving montelukast, and prospective longitudinal studies are needed to further evaluate its psychiatric safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.